Abstract
In Reply.— We appreciate the comments of Kashani, Swensson and Merritt. We are cognizant of the pioneering work done through the years at the University of California at San Diego in relation to the management of respiratory distress syndrome (RDS). The multicenter trial1 established diagnostic criteria for patent ductus arteriosus (PDA) in 1978. In view of the unknown toxicity of indomethacin at that time, high specificity rather than maximum sensitivity was of prime concern. We wanted to enroll in our trial only those infants in whom the degree of ductal shunting was leading to sufficient cardiopulmonary compromise to cause a threat to the infant and to warrant the use of a potentially toxic drug or surgery.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
